Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: FDA

January 25, 2022 Drug delivery / Pharma applications

FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression

— Approval Based on Phase 3 Data Showing Veklury Significantly Reduced Risk of Hospitalization By 87% Compared with Placebo —

Continue reading

January 10, 2022 CD as API / Events / Pharma applications

Virtual Public Meeting: Endpoint Considerations to Facilitate Drug Development for Niemann-Pick Type C (NPC)

On January 24-25, 2022, the FDA and Duke-Margolis Center for Health Policy will host a virtual publicworkshop on endpoint considerations

Continue reading

December 7, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through

Continue reading

November 18, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Submits IND Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

September 21, 2021 Drug delivery / Pharma applications

Marinus Announces FDA Acceptance for Filing and Priority Review of NDA for SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that

Continue reading

September 15, 2021 Drug delivery / Pharma applications

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced

Continue reading

April 29, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

April 22, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

January 14, 2021 Drug delivery / Pharma applications

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder (CDD)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,

Continue reading

November 9, 2020 Drug delivery / Pharma applications

Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (SBECD-enabled fosphenytoin)

Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration

Continue reading

Posts navigation

1 2 3 Next Posts»

Recent Posts

  • Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
  • Waterproof and durable luminescent textiles with HPBCD for marine rescue
  • Small anticancer drug release by light
  • Patent application on reduction of envelope viral particle number in a composition containing cyclodextrin
  • γ-Cyclodextrin/Epigallocatechin-3-gallate Inclusion Complexes as Efficient Antioxidants for Preservation of Shrimp Surimi Products

Tags

alpha-CD antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (35)
  • CD as API (199)
  • CD derivatives (251)
  • Cosmetics and toilettry (21)
  • Drug delivery (416)
  • E-ducation (54)
  • Environmental (76)
  • Events (157)
  • Food (120)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (13)
  • Non-pharma applications (209)
  • Other industrial use (58)
  • Pharma applications (677)
  • Supramolecular systems (25)
  • Uncategorized (41)

Top Posts

  • Lanosterol eye drops for cataract treatment
  • Waterproof and durable luminescent textiles with HPBCD for marine rescue
  • Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
  • γ-Cyclodextrin/Epigallocatechin-3-gallate Inclusion Complexes as Efficient Antioxidants for Preservation of Shrimp Surimi Products
  • Small anticancer drug release by light
  • New book: Cyclodextrins - new Perspectives
  • Cyclodextrin Metal-Organic Framework as a Broad-Spectrum Potential Delivery Vehicle for the Gasotransmitters
  • MIT scientists filed patent for HPBCD treatment in Alzheimer's disease
  • Pilocarpine eye drops (Vuity)
  • Current Overview of Cyclodextrin-Based Nanocarriers for Enhanced Antifungal Delivery

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 521 other subscribers
 

Loading Comments...